US11084809 — N-((HET)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors
Method of Use · Assigned to Kalvista Pharmaceuticals Ltd · Expires 2035-11-26 · 10y remaining
What this patent protects
This patent protects compounds that inhibit kallikrein activity, which can be used in therapy for treating or preventing diseases or conditions associated with plasma kallikrein activity.
USPTO Abstract
The present invention provides compounds of formula (I):compositions comprising such compounds; the use of such compounds in therapy (for example in the treatment or prevention of a disease or condition in which plasma kallikrein activity is implicated); and methods of treating patients with such compounds; wherein R5, R6, R7, A, B, W, X, Y and Z are as defined herein.
Drugs covered by this patent
- Ekterly (SEBETRALSTAT) · Kalvista
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-4223 |
— | Ekterly |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.